NTLA Maintained by Wedbush -- Price Target Raised to $13.00

Gene-editing stocks fell Wednesday after Anthropic's AI model, Claude, identified a phage enzyme system with traits similar to CRISPR. CRISPR Therapeutics (CRSP) dropped 6%, Intellia (NTLA) 3%, Beam (BEAM) 6%, Prime Medicine (PRME) 12%, and Editas Medicine (EDIT) 8%. The discovery, called ART, links an RNA-to-DNA enzyme with repeating DNA and a mystery protein in bacteria-infecting viruses. CRISPR pioneer Feng Zhang called the finding intriguing but unproven.

Intellia Therapeutics (NTLA) awaits FDA decision on lonvo-z for hereditary angioedema (HAE) on March 10, with Phase III data showing 87% attack-rate reduction. The company is preparing for commercial launch, though pricing is undecided. Intellia also advances its TTR amyloidosis study and reports $630M in cash, with a $300M debt facility for funding into 2028.

Intellia Therapeutics (NTLA) outlined a two-track strategy at the Morgan Stanley conference. The FDA accepted its biologics license application for lonvo-z, with a PDUFA date of March 10, 2025. The company reported strong HAE data, including an 87% reduction in attack rate. Intellia has $630M in cash and expects to fund operations into 2028. It is preparing a targeted launch for lonvo-z and is advancing its TTR amyloidosis program, which faces design and competitive questions.

Intellia Therapeutics (NTLA) secured a $400M credit facility with OrbiMed, drawing $75M initially. The remaining $325M is contingent on milestones. The facility has a 9.15% minimum interest rate. NTLA has $628.4M in cash but reported a $106.6M Q2 net loss. The financing supports potential U.S. launch of lonvo-z and other programs.

Intellia Therapeutics (NTLA) announced the FDA accepted and granted priority review to its BLA for lonvoguran ziclumeran, a CRISPR-based therapy for hereditary angioedema (HAE). A decision is expected by March 2027. The therapy showed an 87% reduction in attacks in a phase III study. NTLA shares have risen 41.7% year-to-date. The company also has another CRISPR therapy, nexiguran ziclumeran, in development with Regeneron (REGN).

Intellia Therapeutics' hereditary angioedema treatment, Lonvo-Z, received FDA Priority Review. If approved, it would be the first in vivo CRISPR therapy. The FDA set a PDUFA target action date of March 10, 2027. Lonvo-Z showed an 87% reduction in attacks in a Phase 3 study. Intellia's stock has risen over 35% year-to-date, with ARK Invest recently increasing its stake.